Arcturus Therapeutics Holdings Inc. (ARCT) Share-based Payment Arrangement, Expense USD 2018 - 2024

Historical data

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcturus Therapeutics Holdings Inc. quarterly/annual Share-based Payment Arrangement, Expense history and growth rate from 2018 to 2024.
  • Arcturus Therapeutics Holdings Inc. Share-based Payment Arrangement, Expense for the quarter ending March 31, 2024 was $10.1 M, a 23.3% increase year-over-year.
  • Arcturus Therapeutics Holdings Inc. Share-based Payment Arrangement, Expense for the twelve months ending March 31, 2024 was $36.6 M, a 16.3% increase year-over-year.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2023 was $34.6 M, a 13.2% increase from 2022.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2022 was $30.6 M, a 5.87% increase from 2021.
  • Arcturus Therapeutics Holdings Inc. annual Share-based Payment Arrangement, Expense for 2021 was $28.9 M, a 327% increase from 2020.
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $36.6 M $10.1 M +$1.91 M +23.3% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-08
Q4 2023 $34.6 M $8.82 M +$2.29 M +35% Oct 1, 2023 Dec 31, 2023 10-K 2024-03-14
Q3 2023 $32.4 M $9.27 M -$167 K -1.77% Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-14
Q2 2023 $32.5 M $8.38 M +$1.11 M +15.2% Apr 1, 2023 Jun 30, 2023 10-Q 2023-08-07
Q1 2023 $31.4 M $8.18 M +$811 K +11% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-08
Q4 2022 $30.6 M $6.53 M -$988 K -13.1% Oct 1, 2022 Dec 31, 2022 10-K 2024-03-14
Q3 2022 $31.6 M $9.44 M +$2.57 M +37.4% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-14
Q2 2022 $29 M $7.27 M -$266 K -3.53% Apr 1, 2022 Jun 30, 2022 10-Q 2023-08-07
Q1 2022 $29.3 M $7.37 M +$384 K +5.5% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-09
Q4 2021 $28.9 M $7.52 M +$4.69 M +166% Oct 1, 2021 Dec 31, 2021 10-K 2024-03-14
Q3 2021 $24.2 M $6.87 M +$4.88 M +246% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $19.3 M $7.54 M +$6.44 M +585% Apr 1, 2021 Jun 30, 2021 10-Q 2022-08-09
Q1 2021 $12.9 M $6.99 M +$6.14 M +723% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q4 2020 $6.76 M $2.83 M +$2.03 M +255% Oct 1, 2020 Dec 31, 2020 10-K 2022-03-01
Q3 2020 $4.74 M $1.99 M +$1.61 M +419% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $3.13 M $1.1 M +$698 K +173% Apr 1, 2020 Jun 30, 2020 10-Q 2021-08-10
Q1 2020 $2.43 M $849 K +$450 K +113% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-10
Q4 2019 $1.98 M $797 K Oct 1, 2019 Dec 31, 2019 10-K 2022-03-01
Q3 2019 $383 K -$204 K -34.8% Jul 1, 2019 Sep 30, 2019 10-Q 2020-11-09
Q2 2019 $403 K +$263 K +188% Apr 1, 2019 Jun 30, 2019 10-Q 2020-08-10
Q1 2019 $399 K Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-08
Q3 2018 $587 K Jul 1, 2018 Sep 30, 2018 10-Q 2019-11-08
Q2 2018 $140 K Apr 1, 2018 Jun 30, 2018 10-Q 2019-08-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.